Pharmacodynamic parameters | Estimate (RSE%) | 95% CI |
---|---|---|
Structural parameters | Â | Â |
Baseline PSA (µg/L) | 140a |  |
 Tumor volume on baseline PSA (µg/L)b | 57.5 (38.9%) | 15.5–101.6 |
PSA growth rate (kG) (h−1) | 0.000408 (14.2%) | 0.000286–0.000517 |
Direct drug-induced effect (kD, direct) (L·day−1·GBq−1) | 0.00335 (40.1%) | 0.000961–0.006147 |
Rate constant effect compartment (ke0) (h−1) | 0.00128 (13.1%) | 0.00105–0.00171 |
Delayed drug-induced effect (kD, delay) (L·day−1·MBq−1) | 0.0000328 (17.4%) | 0.0000235–0.0000450 |
Box-cox shape parameter |  −0.822 (28.3%) |  −1.24 to −0.414 |
Inter-individual variability | Â | Â |
Baseline PSA (CV%) | 179 (17.4%) | 151–210 |
kG (CV%) | 90.9 (32.6%) | 64.2–121 |
kD, direct (CV%) | 140 (51.2%) | 61.0–206 |
kD, delay (CV%) | 87.5 (26.1%) | 66.1–109 |
Residual unexplained variability | Â | Â |
Proportional error (CV%) | 29.3 (9.2%) | 27.0–32.2 |